Engineered "hot" core-shell nanostructures for patterned detection of chloramphenicol.

Wenjing Yan,Longping Yang,H. Zhuang,Haizhou Wu,Jianhao Zhang

DOI: https://doi.org/10.1016/j.bios.2015.11.011

2016-04-15

Abstract:

What problem does this paper attempt to address?

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.

Ping Wan,Jianjun Zhang,Xidai Long,Qigen Li,Ning Xu,Ming Zhang,Xiaosong Chen,Longzhi Han,Qiang Xia

DOI: https://doi.org/10.1097/MEG.0000000000000070

2014-01-01

European Journal of Gastroenterology & Hepatology

Abstract:Objective The aim of this study was to assess serum levels of presurgical alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19-9) as prognostic markers in patients with hepatic carcinoma after liver transplantation (LT). Methods A total of 226 patients were recruited for the analysis of serum AFP and CA19-9 levels, on the basis of which the tumor marker type (TMT) was defined and evaluated for prognostic prediction. Overall survival (OS) and relapse-free survival (RFS) were analyzed using Kaplan-Meier curves, and univariate and multivariate Cox models. Results One-year and 5-year OS were 79.0 and 58.0%, respectively, whereas RFS were 70.3 and 62.2%, respectively, in this cohort of patients. There were six variables predicting both OS and RFS, including TMT, tumor size, number of tumor lesions, extrahepatic or vascular invasion, and histopathological grade. Among these, TMT, tumor size, and extrahepatic invasion were all independent predictors of OS and RFS among these patients. Further, on the basis of TMT, novel LT selection criteria for patients with hepatic carcinoma, which supplemented the Milan criteria, were adopted, because the patients within the Milan criteria (n=107) and those exceeding Milan but fulfilling the proposed criteria (n=30) had similar 5-year OS (77.8 vs. 79.3%, P=0.862) and RFS (85.5 vs. 75.1%, P=0.210) rates. Conclusion The data from this study showed that serum levels of preoperative AFP and CA19-9 were able to predict survival of patients with hepatic carcinoma after LT. This study included novel criteria, adding serum AFP and CA19-9 levels to the selection criteria for LT eligibility of patients, in addition to the Milan criteria.
Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation

Xu Zhang,Chi Chen,Yan Wang,Jun Xu

DOI: https://doi.org/10.1111/jgh.16693

2024-08-07

Abstract:Liver transplantation (LT) is an effective method for curing hepatocellular carcinoma (HCC). However postoperative tumor recurrence can lead to higher mortality rates. To select suitable candidates for LT, the Milan Criteria (MC) were first proposed based on tumor morphological characteristics. For those patients who meet the MC, the MC can effectively reduce the postoperative tumor recurrence rate and improve the prognosis of patients undergoing LT. It has always been internationally recognized as the gold standard for selecting candidates for LT, marking a milestone in the history of LT for HCC. However, its strict conditions exclude some HCC patients who could benefit from LT. Therefore, comprehension consideration criteria, including serum biomarkers, tumor histology, and other factor, have been continuously proposed in addition to tumor morphology. This article summaries the prediction model for HCC recurrence after LT from five aspects: tumor morphology, serum markers, histopathology, cellular inflammatory factors and downstaging treatment before transplantation. The aim is to assist clinicians in accurately assessing HCC status, selecting appropriate liver transplant candidates, maximize graft and patients' survival, and optimizing the utilization of social health resources.
Advances in Predicting the Prognosis of Hepatocellular Carcinoma Recipients after Liver Transplantation

Li-ying Wang,Shu-sen Zheng

DOI: https://doi.org/10.1631/jzus.b1700156

2018-01-01

Journal of Zhejiang University SCIENCE B

Abstract:Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors worldwide. Liver transplantation (LT) is known as a curative and therapeutic modality. However, the survival rates of recipients after LT are still not good enough because of tumor recurrence. To improve the survival rates of recipients after LT, identifying predictive factors for prognosis after LT and establishing a model assessing prognosis are very important to HCC patients. There has recently been a lot of clinical and basic research on recurrence and prognosis after LT. Progress has been made, especially in selection criteria for LT recipients and risk factors for predicting prognosis after LT. Hangzhou criteria, in line with China’s high current incidence rate of primary liver, are first proposed by Chinese scholars of LT, and are accepted world-wide, and make an important contribution to the development of LT.
[Selection Criteria for Liver Transplantation Recipients of Hepatocellular Carcinoma].

L P Cao,J Wu

DOI: https://doi.org/10.3760/cma.j.issn.1007-3418.2018.02.002

2018-01-01

Abstract:Liver transplantation is by far the most thorough and effective treatment for liver cancer. However, there is still much controversy about how to select receptors in an effective and equitable manner under the shortage of liver donor. The "Milan Standard" is the most widely used screening standard for liver transplantation recipients in the world. In recent years, many patients with Trans Milan criteria (such as Hangzhou standard) can achieve transplant survival similar to that of Milan patients after transplantation. This article describes the research progress of liver transplantation recipients' selection criteria in hepatocellular carcinoma.
Liver Transplantation for Hepatocellular Carcinoma: A Prognostic Model Incorporating Pretransplant Inflammatory Cytokines.

Ruiqi Sun,Liang Zhang,Zhentao Yang,Ke Zhou,Hong Tang,Wentao Zhao,Ning Wang,Xiaobo Yu,Yiqian Huang,Haiyang Xie,Shusen Zheng,Wu Zhang

DOI: https://doi.org/10.1016/j.cyto.2022.155847

IF: 3.926

2022-01-01

Cytokine

Abstract:Purpose: Liver transplantation (LT) remains an optimal treatment for selected hepatocellular carcinoma (HCC). Cytokines can be obtained by minimally invasive techniques and are associated with the development of HCC. The purpose of our investigation was to explore the prognostic value of pretransplant serum inflammatory cytokine profiles in HCC patients for LT. Methods: We detected forty inflammatory cytokines in pre-LT serum from 42 HCC patients by using an inflammation-related antibody array. A pretransplant serum inflammatory cytokine-associated risk assessment model (pre-SCRAM) was developed and was validated in an external cohort of 213 HCC patients who underwent LT and were then followed prospectively. Results: The pre-LT factors independently associated with recurrence-free survival (RFS) were as follows: B-lymphocyte chemoattractant (BLC), interleukin (IL)-12p40 and maximum tumor diameter. High IL-12P40 level was associated with a significantly smaller maximum tumor diameter (p = 0.021), decreased proportion of nodules >= 3 (p = 0.001), lower platelet counts (p = 0.011) and lower portal vein tumor thrombus (p = 0.031). Conversely, recipients with poor BLC level had higher alpha-fetoprotein (AFP) levels (p = 0.016). Kaplan-Meier analyses revealed that high pre-LT BLC or IL-12p40 level was associated with superior RFS. The pre-SCRAM stratified recipients into three risk groups: high risk, intermediate risk and low risk. In the validation cohort, for patients in the high, intermediate, and low risk groups, the 3-year RFS rates were 29.3%, 58.7%, and 82.2%, respectively, the 3-year HCC-specific survival rates were 54.5%, 73.8%, and 86%, respectively, and the 3-year overall survival rates were 44.4%, 60.9%, and 79.9%, respectively. The pre-SCRAM model performed well and remained significant in optimizing the risk stratification of recurrence in patients beyond the Milan criteria or the AFP model. Conclusion: Pretransplant cytokine profiles can provide powerful prognostic information in the setting of LT for HCC. A pre-LT risk model incorporating cytokines showed excellent efficiency in recurrence prediction for HCC patients, which could ultimately stratify the prognosis in patients beyond the Milan criteria or the AFP model.
Criteria-specific Long-Term Survival Prediction Model for Hepatocellular Carcinoma Patients after Liver Transplantation

Fei Teng,Gui-Hua Wang,Yi-Feng Tao,Wen-Yuan Guo,Zheng-Xin Wang,Guo-Shan Ding,Xiao-Min Shi,Zhi-Ren Fu

DOI: https://doi.org/10.3748/wjg.v20.i31.10900

IF: 5.374

2014-01-01

World Journal of Gastroenterology

Abstract:AIM: To establish a model to predict long-term survival of hepatocellular carcinoma(HCC) patients after liver transplantation(MHCAT).METHODS: Two hundred and twenty-three patients with HCC were followed for at least six years to identify independent risk factors for long-term survival after liver transplantation(LT). The criteria for HCC liver transplantation included the Milan, University of California San Francisco, Hangzhou and Shanghai Fudan criteria. The Cox regression model was used to build MHCAT specifying these criteria. A survival analysis was carried out for patients with high or low risk.RESULTS: The one-, three- and five-year cumulativesurvival of HCC patients after LT was 78.9%, 53.2% and 46.4%, respectively. Of the HCC patients, the proportion meeting the Hangzhou and Fudan criteria was significantly higher than the proportion meeting the Milan criteria(64.6% vs 39.5%, 52.0% vs 39.5%, P < 0.05). Moreover, the proportion meeting the Hangzhou criteria was also significantly higher than the proportion meeting other criteria(P < 0.01). Pre-operative alfa-fetoprotein level, intraoperative blood loss and retransplantation were common significant predictors of long-term survival in HCC patients with reference to the Milan, University of California San Francisco and Fudan criteria, whereas in MHCAT based on the Hangzhou criteria, total bilirubin, intraoperative blood loss and retransplantation were independent predictors. The c-statistic for MHCAT was 0.773-0.824, with no statistical difference among these four criteria. According to the MHCAT scoring system, patients with low risk showed a higher five-year survival than those with high risk(P < 0.001).CONCLUSION: MHCAT can effectively predict longterm survival for HCC patients, but needs to be verified by multi-center retrospective or randomized controlled trials.
The clinical value of "Hangzhou Criteria" in the selection of patients with hepatocellular carcinoma for liver transplantation: a report of 1163 cases on a multi-center basis

徐骁,杨家印,钟林,鲁迪,庄润周,屠振华,陈峻,王伟林,张珉

DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2013.09.004

2013-01-01

Abstract:Objective To explore a valid candidate selecting criteria for liver transplantation (LT) in patients with primary hepatocellular carcinoma (HCC),and to investigate the clinical value of Hangzhou Criteria.Method This study retrospectively reviewed 1163 HCC patients undergoing LT,and the characteristics of recruited recipient population and the prognosis-predicting ability of different criteria were compared.Result In the 1163 recipients,the number of patients fulfilling Milan Criteria,Hangzhou Criteria,and UCSF Criteria was 424 (36.4％),645 (55.5％),and 484(41.6％),retrospectively.Compared to Milan Criteria,Hangzhou Criteria and UCSF Criteria provided an expansion of 52.1％ and 14.2％,respectively.For non-cirrhosis HCC patients,Hangzhou Criteria could provide the largest expansion to the candidate pool,which was 133.3％.For the recipients fulfilling different criteria,the prognosis was comparable.Hangzhou Criteria functioned well in predicting tumor-recurrence.The 1-,3-,and 5-years overall survival rate for patients fulfilling Hangzhou Criteria was significantly higher than that of patients exceeding Hangzhou Criteria (85.9％,73.6％,and 66.4％ versus 60.7％,26.2％,and 20.7％,respectively,P＜0.001).And the1,3,and 5-year tumor-free survival rate for patients fulfilling Hangzhou Criteria was also significantly higher than that of patients exceeding Hangzhou Criteria (78.8％,65.1％,and 60.8％ versus 37.2％,20.0％,and 18.8％,respectively,P＜0.001).Conclusion There is no dispute in the ethics Committee and all the donor's family members about the usage of ECMO.The ECMO support DBCD could well control the warm ischemia,and obtain satisfactory curative effect of transplantation.
Expanded Criterion for Hepatocellular Carcinoma in Liver Transplantation

MA Shao-hua,ZHANG Tong-lin,XIU Dian-rong,SONG Shi-bing,WANG Chang-ming,JIANG Bin,ZHAO Yi-ming

DOI: https://doi.org/10.3760/cma.j.issn.1007-631x.2009.02.014

2009-01-01

Abstract:Objective To evaluate the effects of different selection criteria on the prognosis of hepatocellular carcinoma(HCC)patients undergoing liver transplantation(LT)and to evaluate a new criterion.Methods A retrospective analysis was performed on 81 consecutive patients with HCC who underwent LT.The survival rates of the patients who met different criteria such as Milan.UCSF(University of California San Francisco UCSF).and Pittsburgh(Pitt)modified TNM criteria were calculated by KaplanMeier method,and the value of different criteria was evaluated.The Long-Rank test and COX proportional hazards regression model were performed to analyze the prognostic factors.the model of criteria was established according the most important prognostic factors.Using the Kaplan-Meier method,the suitable cut-offs of every variable ifl the model were found by comparing the survival and the number of the patients who met the cut-off,and considering the significant difference between the patients who met and exceed the cut-off at the same time.Resuits The 1,2,3-year accumulative survival rates of the 19 patients who met Milan criteria were 87.7%,87.7%,and 52.6%respectively:the 1,2,3-year disease free survival rates of them were 88.9%,72.7%,and 72.7%respectively.The 1,2.3-year accumulative survival rates of the 26 patients who met UCSF criteria were 87.2%,80.5%,and 55.2%respectively;the 1,2,3-year disease free survival rates of them were 84.1%,68.4%,and 68.4%respectively.With our new expanded criterion as of solitary tumor≤8 cm in diameter.or no more than 3 tumors,with the largest≤6 am,and a total tumor diameter≤10 cm.there was no significant difierence in 1,2,3-year sunrival rates and disease free survival rates(89.0%,81.8%,71.8%,and 81.9%,72.4%,72.4%.)as compared with Milan or UCSF criteria.but with this new criterion more patients(a=41)would be eligible for transplantation with a comparable long term survival.and the difference of the accumulative survival rates and disease free survival rates of the patients who met and exceed the new criteria was significant(P＜0.05).Conclusion The new indication is acceptable because the criteria does not adversely impact survival.
Liver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds?

Tsuyoshi Shimamura,Ryoichi Goto,Masaaki Watanabe,Norio Kawamura,Yasutsugu Takada

DOI: https://doi.org/10.3390/cancers14020419

2022-01-14

Cancers

Abstract:Hepatocellular carcinoma (HCC) is the third highest cause of cancer-related mortality, and liver transplantation is the ideal treatment for this disease. The Milan criteria provided the opportunity for HCC patients to undergo LT with favorable outcomes and have been the international gold standard and benchmark. With the accumulation of data, however, the Milan criteria are not regarded as too restrictive. After the implementation of the Milan criteria, many extended criteria have been proposed, which increases the limitations regarding the morphological tumor burden, and incorporates the tumor’s biological behavior using surrogate markers. The paradigm for the patient selection for LT appears to be shifting from morphologic criteria to a combination of biologic, histologic, and morphologic criteria, and to the establishment of a model for predicting post-transplant recurrence and outcomes. This review article aims to characterize the various patient selection criteria for LT, with reference to several surrogate markers for the biological behavior of HCC (e.g., AFP, PIVKA-II, NLR, 18F-FDG PET/CT, liquid biopsy), and the response to locoregional therapy. Furthermore, the allocation rules in each country and the present evidence on the role of down-staging large tumors are addressed.

oncology
Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?

Zhi Dai,Lei Yu,Jian Zhou,Shuang-Jian Qiu,Jia Fan

DOI: https://doi.org/10.1586/egh.09.12

2009-01-01

Expert Review of Gastroenterology & Hepatology

Abstract:Currently, hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide; 82% of the cases occur in developing countries, with 55% occurring in China [1]. Liver transplantation (LT), a potentially curative thera peutic modality of HCC, allows radical extirpation of the cancer and restores normal liver function. There is increasing evidence that, in the long term, LT will be the best therapeutic option for cirrhosis-associated HCC [2]. Unfortunately, the recurrence rate is high in HCC patients who undergo LT, which markedly reduces the longterm and medium-term survival of HCC patients [3]. Therefore, risk estimation of post-transplant tumor recurrence is an essential element in selecting a subset of HCC patients for LT. In clinical practice, this risk estimation is based on the number and size of the nodules, and microscopic/macroscopic vascular invasion; and selection criteria for LT have been established to select HCC patients according to these clinical features. The Milan criteria proposed by Mazzaferro and his colleagues – a single lesion of 5 cm or smaller in diameter, or three lesions each smaller than 3 cm in diameter, and without macroscopic vascular invasion – have been accepted worldwide for identifying candidates with good prognosis and low recurrence rates [4]. The Milan criteria were chosen in an attempt to minimize the difference in outcomes between transplanted HCC patients and those who did not have HCC, and these criteria have been adopted for organ allocation in the USA and in Europe [5,6]. Despite their proven utility, many recent data have suggested that these criteria are too restrictive, and many patients with tumor burdens outside the Milan criteria may potentially benefit from LT. Moreover, limiting LT to HCC patients within the Milan criteria may be unjust for those outside of the criteria who could have a favorable outcome with LT. Several expansions of the Milan criteria have been proposed. Yao and coworkers at the University of California, San Francisco (UCSF; CA, USA) reported that LT candidates with a solitary tumor of 6.5 cm in diameter or smaller, or three or fewer nodules with the largest lesion no larger than 4.5 cm in diameter, and a total tumor diameter no larger than 8 cm (the so-called UCSF criteria) achieved excellent results following LT that were not different from those for HCC patients within the Milan criteria [7]. Although the UCSF criteria have been validated by several groups [8], these criteria have not been accepted unanimously, which may be related to the results of a large multi center study that suggested the UCSF criteria to be associated with a 5-year survival rate of less than 50% when applied to preoperative evaluation [9]. In addition, the UCSF criteria allow LT for large tumors, which have been proven to be associated with post-transplant metastatic recurrence [10]. Lastly, both the Milan and the UCSF criteria exclude those patients with more than three nodules, who may obtain good outcomes if the tumors are of a reasonable size. Toso and his colleagues proposed an expansion of the current allocation criteria Zhi Dai, PhD Liver Cancer Institute, Shanghai 200032, PR China dai.zhi@zs-hospital.sh.cn
Prognostic Indicators for Tumor Recurrence after Liver Transplantation in Hepatocellular Carcinoma and Related Molecular Targeted Therapy.

Lei Yu,Zhi Dai,Zheng Wang,Jia Fan,Jian Zhou

DOI: https://doi.org/10.1159/000333273

2011-01-01

Oncology

Abstract:Liver transplantation (LT) is a viable therapeutic option for hepatocellular carcinoma (HCC). Many criteria, such as the Milan criteria and the University of California at San Francisco (UCSF) criteria, have been established to select a subset of HCC patients who stand to benefit from LT. However, they are still insufficient for predicting HCC patients at high risk for recurrence and selecting those at low risk. Many molecules which are probable candidates for recognizing HCC patients at high or low risk for recurrence give a wider perspective to consider for LT indication. Besides working as biomarkers, most of them are also functionally involved in some important pathways which contribute to HCC metastasis. The complex network constituted by them shows a multichannel, multistep HCC metastatic process which indicates difficulty in tumor therapy. Given the efficacy of some molecular targeted drugs in the treatment of HCC or prevention of tumor recurrence after LT, the emerging molecular targeted therapy is also discussed in this review.
Development of a nomogram for predicting liver transplantation prognosis in hepatocellular carcinoma

Li He,Wan-Sheng Ji,Hai-Long Jin,Wen-Jing Lu,Yuan-Yuan Zhang,Hua-Guang Wang,Yu-Yu Liu,Shuang Qiu,Meng Xu,Zi-Peng Lei,Qian Zheng,Xiao-Li Yang,Qing Zhang

DOI: https://doi.org/10.3748/wjg.v30.i21.2763

2024-06-07

Abstract:Background: At present, liver transplantation (LT) is one of the best treatments for hepatocellular carcinoma (HCC). Accurately predicting the survival status after LT can significantly improve the survival rate after LT, and ensure the best way to make rational use of liver organs. Aim: To develop a model for predicting prognosis after LT in patients with HCC. Methods: Clinical data and follow-up information of 160 patients with HCC who underwent LT were collected and evaluated. The expression levels of alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin, Golgi protein 73, cytokeratin-18 epitopes M30 and M65 were measured using a fully automated chemiluminescence analyzer. The best cutoff value of biomarkers was determined using the Youden index. Cox regression analysis was used to identify the independent risk factors. A forest model was constructed using the random forest method. We evaluated the accuracy of the nomogram using the area under the curve, using the calibration curve to assess consistency. A decision curve analysis (DCA) was used to evaluate the clinical utility of the nomograms. Results: The total tumor diameter (TTD), vascular invasion (VI), AFP, and cytokeratin-18 epitopes M30 (CK18-M30) were identified as important risk factors for outcome after LT. The nomogram had a higher predictive accuracy than the Milan, University of California, San Francisco, and Hangzhou criteria. The calibration curve analyses indicated a good fit. The survival and recurrence-free survival (RFS) of high-risk groups were significantly lower than those of low- and middle-risk groups (P < 0.001). The DCA shows that the model has better clinical practicability. Conclusion: The study developed a predictive nomogram based on TTD, VI, AFP, and CK18-M30 that could accurately predict overall survival and RFS after LT. It can screen for patients with better postoperative prognosis, and improve long-term survival for LT patients.
Role of Pittsburgh Modified TNM Criteria in Prognosis Prediction of Liver Transplantation for Hepatocellular Carcinoma.

Chen Jun,Xu Xiao,Ling Qi,Wu Jian,Zheng Shu-sen

DOI: https://doi.org/10.1097/00029330-200712020-00008

2007-01-01

Abstract:BACKGROUND:Pittsburgh modified TNM criteria is one of the prognostic models of orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC). In this study, we applied this prognostic system in a series of HCC patients receiving OLT to verify its reliability in the clinical prognostic prediction.METHODS:The clinical record and follow-up data of 102 patients with HCC underwent OLT was collected. The patients were classified by 3 staging systems: the Pittsburgh Modified TNM Criteria, International Union Against Cancer (UICC) pTNM Staging System, and Milan Criteria. Survival rates of the patients were analyzed using the Kaplan-Meier method and the Log-Rank test, and then the prognostic values of the 3 staging systems were compared.RESULTS:Among the 3 staging systems, the Pittsburgh Modified TNM Criteria showed the best stratification of patients with different prognosis. The overall survival rates of the patients at the Pittsburgh modified TNM stage I, II, III, and IV were 94.4%, 83.3%, 58.2%, and 36.8% at 1 year, and 79.4%, 62.5%, 26.2%, and 10.5% at 3 years, respectively. For those patients exceeding the Milan Criteria, the patients at Pittsburgh stages I and II had a significant higher survival rate than those at Pittsburgh stages III and IV (P < 0.001).CONCLUSIONS:The Pittsburgh Modified TNM Criteria is a more reliable postoperative staging system than the UICC pTNM staging system for HCC patients receiving OLT. As providing more accurate prognostic classification, it could be reasonable to combine the Milan Criteria for recipient selection.
Value of Liver Transplantation in Hepatocellular Carcinoma Treatment

Shu-sen Zheng,Jian Wu

DOI: https://doi.org/10.3321/j.issn:1000-503x.2008.04.002

2008-01-01

Abstract:Along with the improvement of surgical techniques and post-transplant management, the role of liver transplantation in hepatocellular carcinoma (HCC) treatment has become increasingly important. Although HCC now is an indication of liver transplantation, the criteria of HCC candidates selection vary in different transplantation centers in China. On the contrary, the HCC candidates selection criteria in western countries are relatively strict, among which Milan criteria, University of California, San Francisco (UCSF) criteria, and Pittsburgh modified TNM criteria are widely acknowledged. However, Milan criteria and UCSF criteria only focus on tumor diameter and tumor number but ignore some important risk factors such as vascular invasion and histological differentiation. In our opinion, the biological behaviors of tumor are as important as tumor burden. A set of new candidates selection and prognostic criteria of liver transplantation in HCC patients named "Hangzhou criteria" has been established based on China's real situations and on the results of our long-term research. Hangzhou criteria expands and surpasses Milan criteria, including several important risk factors. According to Hangzhou criteria, more HCC patients are given opportunities to receive liver transplantation and achieved favorable long-term survival. Also in this article, we reviewed the peri-transplantation therapy of HCC to reduce the tumor recurrence and improve the long-term survival after transplantation for the purpose of making liver transplantation more effective and reliable for HCC treatment.
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

B. Łągiewska,Wojciech Straś,J. Gotlib,W. Lisik,P. Małkowski,M. Hreńczuk,D. Wasiak,O. Tronina

DOI: https://doi.org/10.12659/AOT.934924

2022-01-25

Annals of Transplantation

Abstract:Liver transplantation (LTx) is the best treatment for patients with early-stage hepatocellular carcinoma (HCC). The Milan criteria positively influenced results of liver transplantation and were adopted by the majority of cancer centers, becoming the criterion standard treatment for early-stage HCC. Despite the use of restrictive criteria, recurrence is still high, affecting between 8% and 20% of cases, and is a significant predictor of survival after LTx. The diagnosis of both micro-and macro-invasion of vessels, which are significant factors in determining the frequency of recurrence and overall survival, significantly decreases the success of transplantation, causing an increase in mortality of 50% in comparison to recipients with no vascular invasion. The risk of recurrence depends on several factors, which are discussed in this review. The authors also discuss the clinical presentation and treatment methods of recurrence and its prognosis. In addition, the role of different models developed to identify groups of patients with high versus low risk of recurrence is discussed, enabling the planning of recommendations and screening protocols after transplantation to help early diagnosis and guide effective treatment. In the era of an increasing numbers of liver transplants due to HCC, the need to create robust screening tools is urgent.

Medicine
A Score Model for Predicting Post-Liver Trans- Plantation Survival in HBV Cirrhosis-Related Hepatocellular Carcinoma Recipients： a Single Center 5-Year Experience

Li-Ying Wang,Shu-Sen Zheng,Xiao Xu,Wei-Lin Wang,Jian Wu,Min Zhang,Yan Shen,Sheng Yan,Hai-Yang Xie,Xin-Hua Chen,Tian-An Jiang,Fen Chen

DOI: https://doi.org/10.1016/s1499-3872(15)60335-6

IF: 3.355

2015-01-01

Hepatobiliary & Pancreatic Diseases International

Abstract:BACKGROUND: The prognostic prediction of liver transplantation (LT) guides the donor organ allocation. However, there is currently no satisfactory model to predict the recipients' outcome, especially for the patients with HBV cirrhosis-related hepatocellular carcinoma (HCC). The present study was to develop a quantitative assessment model for predicting the post-LT survival in HBV-related HCC patients.METHODS: Two hundred and thirty-eight LT recipients at the Liver Transplant Center, First Affiliated Hospital, Zhejiang University School of Medicine between 2008 and 2013 were included in this study. Their post-LT prognosis was recorded and multiple risk factors were analyzed using univariate and multivariate analyses in Cox regression.RESULTS: The score model was as follows: 0.114x (Child-Pugh score)-0.002x (positive HBV DNA detection time)+0.647x (number of tumor nodules)+0.055x (max diameter of tumor nodules)+0.231xlnAFP+0.437x (tumor differentiation grade). The receiver operating characteristic curve analysis showed that the area under the curve of the scoring model for predicting the post-LT survival was 0.887. The cut-off value was 1.27, which was associated with a sensitivity of 72.5% and a specificity of 90.7%, respectively.CONCLUSION: The quantitative score model for predicting post-LT survival proved to be sensitive and specific.
Prognostic Evaluation of Candidate Selection Hangzhou Criteria of Hepatocellular Carcinoma for Liver Transplantation after Hepatectomy

Fang Haixing,Lu Di,Zhuo Jianyong,Yuan Nianyong,Zhang Shiwei,Wang Kun,Xu Xiao,Zheng Shusen

DOI: https://doi.org/10.3760/cma.j.issn.1007-631x.2018.11.003

2018-01-01

Abstract:Objective To evaluate the prognostic significance of the candidate selection Hangzhou criteria for liver transplantation of HCC patients undergoing hepatectomy.Methods 199 HCC patients undergoing hepatectomy between 2009 and 2011 were enrolled retrospectively.Predictors of survival were identified using the Kaplan-Meier method.The disease state was staged by the Hangzhou criteria (HC) and Milan staging systems.Calculating the area under the receiver operating characteristic (ROC) curve (AUC) evaluates the discriminatory ability for the prediction of survival of both staging system.Results Portal vein thrombosis,poor differentiation,and tumor size (＞ 8 cm) were independent risk factors for survival after hepatectomy.Milan criteria and Hangzhou criteria functioned well in predicting tumor-recurrence.For 1-year AUROC,the AUROC for Milan criteria and Hangzhou criteria are 0.602 and 0.741,respectively.For 3-year AUROC,the AUROC for Milan criteria and Hangzhou criteria are 0.643 and 0.733,respectively.Conclusions The HC were shown to be a promising survival predictor in a Chinese cohort of HCC patients after hepatectomy.
[Liver Transplantation for Hepatocellular Carcinoma: Prognostic Analysis of 89 Cases].

Shu-sen Zheng,Xiao Xu,Ting-bo Liang,Wei-lin Wang,Yan Shen,Min Zhang,Jian Wu,An-wei Lu,Zhe-xin Shao

DOI: https://doi.org/10.3760/j:issn:0529-5815.2005.07.013

2005-01-01

Abstract:OBJECTIVE:To summarize the experience of liver transplantation (LT) for hepatocellular carcinoma (HCC) in one center and identify prognostic factors for survival.METHODS:The clinical data and survival results of 89 patients with HCC receiving LT from January 1999 to December 2003 were retrospectively analyzed and various clinicopathologic risk factors for actuarial survival and tumor free survival were evaluated by univariate and multivariate analysis.RESULTS:Six-month, 1-, and 2-year survival rates were 81.8%, 55.3% and 43.7%, respectively. The 6-month, 1-, and 2-year tumor free survival rates were 62.4%, 35.6% and 24.9%, respectively. The overall tumor recurrence and metastasis rate was 52.8%. In the univariate analysis, portal vein tumor thrombi (PVTT) (chi(2) = 15.14, P = 0.0001), tumor size (chi(2) = 15.05, P = 0.0001), hepatic cirrhosis background (chi(2) = 6.14, P = 0.0132), preoperative alpha-fetoprotein (AFP) level (chi(2) = 5.82, P = 0.0159) and histopathologic grading (chi(2) = 4.61, P = 0.0319) were found to be significantly associated with actuarial survival rate. Seven factors influencing tumor free survival included PVTT (chi(2) = 26.30, P < 0.0001), tumor size (chi(2) = 25.25, P < 0.0001), preoperative AFP level (chi(2) = 14.83, P = 0.0001), histopathologic grading (chi(2) = 12.54, P = 0.0004), tumor distribution (chi(2) = 12.73, P = 0.0004), number of nodules (chi(2) = 9.81, P = 0.0017) and cirrhosis background (chi(2) = 9.76, P = 0.0018). In the multivariate Cox regression analysis, the prognostic factors independently associated with patient survival were identified to be PVTT (RR = 4.721, P = 0.001), age (RR = 3.282, P = 0.007) and histopathologic grading (RR = 2.368, P = 0.037). For tumor free survival, histopathologic grading (RR = 3.739, P < 0.0001), PVTT (RR = 4.382, P = 0.001), cirrhosis background (RR = 0.421, P = 0.011), age (RR = 2.312, P = 0.027) and AFP (RR = 2.301, P = 0.047) were identified as prognostic parameters.CONCLUSIONS:LT is a good therapeutic option for strictly selected patients with HCC. PVTT and histopathologic grading are the most important factors of predicting outcomes of HCC patients undergoing LT. Further studies should be strengthened to establish a reliable and feasible selection criteria and an optimal prognosis scoring system for LT.
Gastroretentive Dosage Forms for Prolonging Gastric Residence Time

Ritesh Kumar,A. Philip

DOI: https://doi.org/10.2165/00124363-200721020-00005

2007-04-01

International Journal of Pharmaceutical Medicine

Abstract:
Model to Predict Overall Survival in Patients With Hepatocellular Carcinoma After Curative Hepatectomy

Li-xiang Zhang,Pan-quan Luo,Lei Chen,Dong-da Song,A-man Xu,Peng Xu,Jia Xu

DOI: https://doi.org/10.3389/fonc.2020.537526

IF: 4.7

2021-03-05

Frontiers in Oncology

Abstract:Background The prognosis of patients with hepatocellular carcinoma (HCC) remains difficult to accurately predict. The purpose of this study was to establish a prognostic model for HCC based on a novel scoring system. Methods Five hundred and sixty patients who underwent a curative hepatectomy for treatment of HCC at our hospital between January 2007 and January 2014 were included in this study. Univariate and multivariate analyses were used to screen for prognostic risk factors. The nomogram construction was based on Cox proportional hazard regression models, and the development of the new scoring model was analyzed using receiver operating characteristic (ROC) curve analysis and then compared with other clinical indexes. The novel scoring system was then validated with an external dataset from a different medical institution. Results Multivariate analysis showed that tumor size, portal vein tumor thrombus (PVTT), invasion of adjacent tissues, microvascular invasion, and levels of fibrinogen and total bilirubin were independent prognostic factors. The new scoring model had higher area under the curve (AUC) values compared to other systems, and the C-index of the nomogram was highly consistent for evaluating the survival of HCC patients in the validation and training datasets, as well as the external validation dataset. Conclusions Based on serum markers and other clinical indicators, a precise model to predict the prognosis of patients with HCC was developed. This novel scoring system can be an effective tool for both surgeons and patients.

oncology

Engineered "hot" core-shell nanostructures for patterned detection of chloramphenicol.

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.

Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation

Advances in Predicting the Prognosis of Hepatocellular Carcinoma Recipients after Liver Transplantation

[Selection Criteria for Liver Transplantation Recipients of Hepatocellular Carcinoma].

Liver Transplantation for Hepatocellular Carcinoma: A Prognostic Model Incorporating Pretransplant Inflammatory Cytokines.

Criteria-specific Long-Term Survival Prediction Model for Hepatocellular Carcinoma Patients after Liver Transplantation

The clinical value of "Hangzhou Criteria" in the selection of patients with hepatocellular carcinoma for liver transplantation: a report of 1163 cases on a multi-center basis

Expanded Criterion for Hepatocellular Carcinoma in Liver Transplantation

Liver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds?

Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?

Prognostic Indicators for Tumor Recurrence after Liver Transplantation in Hepatocellular Carcinoma and Related Molecular Targeted Therapy.

Development of a nomogram for predicting liver transplantation prognosis in hepatocellular carcinoma

Role of Pittsburgh Modified TNM Criteria in Prognosis Prediction of Liver Transplantation for Hepatocellular Carcinoma.

Value of Liver Transplantation in Hepatocellular Carcinoma Treatment

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

A Score Model for Predicting Post-Liver Trans- Plantation Survival in HBV Cirrhosis-Related Hepatocellular Carcinoma Recipients： a Single Center 5-Year Experience

Prognostic Evaluation of Candidate Selection Hangzhou Criteria of Hepatocellular Carcinoma for Liver Transplantation after Hepatectomy

[Liver Transplantation for Hepatocellular Carcinoma: Prognostic Analysis of 89 Cases].

Gastroretentive Dosage Forms for Prolonging Gastric Residence Time

Model to Predict Overall Survival in Patients With Hepatocellular Carcinoma After Curative Hepatectomy